doi: 10.21147/j.issn.1000-9604.2022.05.05.
Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)
Affiliations
- PMID: 36398118
- PMCID: PMC9646454
- DOI: 10.21147/j.issn.1000-9604.2022.05.05
Item in Clipboard
Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)
Chin J Cancer Res.
.
No abstract available
Similar articles
-
Comments on National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version).Chin J Cancer Res. 2023 Oct 30;35(5):431-432. doi: 10.21147/j.issn.1000-9604.2023.05.01. Chin J Cancer Res. 2023. PMID: 37969963 Free PMC article. No abstract available.
-
Comments on National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version).Chin J Cancer Res. 2022 Oct 30;34(5):453-455. doi: 10.21147/j.issn.1000-9604.2022.05.04. Chin J Cancer Res. 2022. PMID: 36398128 Free PMC article. No abstract available.
-
Comments on National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version).Chin J Cancer Res. 2022 Oct 30;34(5):458-459. doi: 10.21147/j.issn.1000-9604.2022.05.06. Chin J Cancer Res. 2022. PMID: 36398122 Free PMC article. No abstract available.
-
[Quality assessment of global prostate cancer screening guidelines].Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Feb 10;42(2):227-233. doi: 10.3760/cma.j.cn112338-20200806-01033. Zhonghua Liu Xing Bing Xue Za Zhi. 2021. PMID: 33626608 Chinese.
-
[Systematic review of the methodology quality and reporting quality in colorectal cancer screening guidelines].Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Apr 6;53(4):398-404. doi: 10.3760/cma.j.issn.0253-9624.2019.04.013. Zhonghua Yu Fang Yi Xue Za Zhi. 2019. PMID: 30982275 Chinese.
Cited by
-
The role of TLRs (microbe recognition receptor) in gastric cancer: An update.Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9641-9657. doi: 10.1007/s00210-025-03966-7. Epub 2025 Mar 10. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40063240 Review.
-
Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients.Eur J Med Res. 2023 Jul 22;28(1):245. doi: 10.1186/s40001-023-01215-2. Eur J Med Res. 2023. PMID: 37480146 Free PMC article.
-
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.Chin J Cancer Res. 2023 Aug 30;35(4):424-430. doi: 10.21147/j.issn.1000-9604.2023.04.08. Chin J Cancer Res. 2023. PMID: 37691892 Free PMC article.
-
Establishment of novel ferroptosis-related prognostic subtypes correlating with immune dysfunction in prostate cancer patients.Heliyon. 2023 Dec 9;10(1):e23495. doi: 10.1016/j.heliyon.2023.e23495. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187257 Free PMC article.
-
Prediction of prostate cancer aggressiveness using magnetic resonance imaging radiomics: a dual-center study.Discov Oncol. 2024 Apr 16;15(1):122. doi: 10.1007/s12672-024-00980-8. Discov Oncol. 2024. PMID: 38625419 Free PMC article.
References
-
-
Office of the Healthy Beijing Action Promotion Committee, Beijing Center for Disease Prevention and Control. The Beijing Population Health Status Report 2020. Beijing: People’s Medical Publishing House, 2021.
-
LinkOut - more resources
Full Text Sources